3. Discussion
Spasticity, disability, spasticity, pain
ADVERSE EVENTS, SECONDARY
This phase 3 clinical trial is the first randomized, double-blind, active-drug-controlled study to compare the efficacy and safety of LiztoxBTX-A typically reaches its maximum effectiveness within about a week and tends to diminish in efficacy after 3 to 4 months [Spasticity is characterized by an increase in muscle tone that depends on speed or a tonic stretch reflex. This condition can hinder movement and is often associated with discomfort or pain. However, using only the MAS may not adequately reflect the extent of functional deficits and disability caused by spasticity, necessitating a comprehensive clinical evaluation. Therefore, as secondary outcomes, we evaluated disability from spasticity, upper limb function using the DAS and CBS, and overall treatment effectiveness using the SGA and IGA. In the current study, the DAS scores displayed notable improvement throughout the entire 12-week duration, aligning with prior research findings indicating that upper limb function, as assessed using the DAS, improved following the administration of BTX-A (Although there was a general decline in treatment effectiveness over time, the influence of BTX-A on the MAS scores remained consistent for 12 weeks after the intervention. When comparing the BotoxA notable improvement in MAS grade following BTX-A injection has been consistently reported in various studies, and our study showed similar efficacy with LiztoxRegarding safety, all adverse events documented during this study were categorized as mild or moderate, and no adverse events resulting in fatalities were recorded. Furthermore, there were no notable disparities in the safety assessment between the Liztox